Collegium Pharmaceutical (COLL) Capital Expenditures (2015 - 2026)

Collegium Pharmaceutical's Capital Expenditures history runs 12 years deep, the most recent figure standing at $270000.0 for Q1 2026.

• In Q1 2026, Capital Expenditures fell 66.17% year-over-year to $270000.0; the TTM figure through Mar 2026 stood at -$209000.0 (down 111.11% YoY), while the FY2025 annual figure was $319000.0, down 80.69% from the prior year.
• Capital Expenditures was $270000.0 for Q1 2026 at Collegium Pharmaceutical, up from $5000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $940000.0 in Q4 2022 to a low of -$674000.0 in Q2 2025.
• Historically, Capital Expenditures has averaged $254352.9 across 5 years, with a median of $176000.0 in 2023.
• Biggest YoY gain for Capital Expenditures was 1256.92% in 2024; the steepest drop was 757.14% in 2024.
• A 5-year view of Capital Expenditures shows it stood at $940000.0 in 2022, then sank by 82.55% to $164000.0 in 2023, then soared by 247.56% to $570000.0 in 2024, then sank by 99.12% to $5000.0 in 2025, then surged by 5300.0% to $270000.0 in 2026.
• The last three Capital Expenditures figures came in at $270000.0 (Q1 2026), $5000.0 (Q4 2025), and $190000.0 (Q3 2025), per Business Quant data.